Presenting the results of the 1200-strong ENDEAVOR II trial here at the American College of Cardiology 2005 Scientific Sessions, Dr William Wijns (OLV Ziekenhuis, Aalst, Belgium) declared, "The results of this trial establish the Endeavor stent as a viable treatment option for patients undergoing angioplasty with drug-eluting stents [DES]."